Related Experiment Video
Updated: Jul 8, 2026
08:21
Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
A cardiologist's perspective on cardiometabolic risk
1Vascular Disease Prevention Program, Cardiovascular Division, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. jplutzky@rics.bwh.harvard.edu
The American Journal of Cardiology
|December 25, 2007
Summary
Many patients evaluated for heart disease have metabolic syndrome, a condition driven by metabolic abnormalities that accelerate atherosclerosis. Targeting adiposity is crucial for managing this syndrome and its cardiovascular risks.
Area of Science:
- Cardiology
- Metabolic Disorders
- Atherosclerosis Research
Background:
- Metabolic syndrome is prevalent in patients undergoing cardiovascular evaluation.
- The metabolic abnormalities of this syndrome are key contributors to atherosclerosis development.
- Adiposity is recognized as a central component of metabolic syndrome.
Purpose of the Study:
- To highlight the significance of metabolic syndrome in cardiovascular evaluations.
- To emphasize the role of adiposity in metabolic syndrome.
- To underscore the need for cardiologists to address adiposity.
Main Methods:
- Review of National Cholesterol Education Program (NCEP) criteria.
- Analysis of existing data linking metabolic abnormalities to atherosclerosis.
- Assessment of the role of adiposity in metabolic syndrome pathophysiology.
Main Results:
- A significant proportion of cardiovascular patients meet NCEP criteria for metabolic syndrome.
- Metabolic syndrome's characteristic abnormalities are major drivers of atherosclerosis.
- Adiposity is consistently implicated as a core feature of metabolic syndrome.
Conclusions:
- Understanding and targeting adiposity is essential for cardiologists managing patients with metabolic syndrome.
- Addressing adiposity may be a key therapeutic strategy for mitigating cardiovascular risk in these patients.
- Further research into the management of adiposity within metabolic syndrome is warranted.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...